Sichuan Biokin Pharmaceutical's unit receives milestone payment from Bristol-Myers Squibb
BMY•A unit of Sichuan Biokin Pharmaceutical received a second $250 million milestone payment from Bristol-Myers Squibb under their iza-bren agreement.
1. Second milestone payment
Sichuan Biokin Pharmaceutical said its unit received a second milestone payment of $250 million from Bristol-Myers Squibb for the iza-bren agreement.




